| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 43.730 | 38.987 | 48.415 | 0 | 4.717 | 217 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 43.730 | 38.987 | 48.415 | 1.705 | 4.717 | 218 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 43.259 | 41.389 | 49.283 | 395 | 3.410 | 385 | 127 | 41 | 40 | 40 |
| Gross Profit/Loss - EUR | 472 | -2.402 | -868 | 1.310 | 1.307 | -167 | -127 | -41 | -40 | -40 |
| Net Profit/Loss - EUR | -842 | -2.792 | -1.352 | 1.259 | 1.165 | -173 | -127 | -41 | -40 | -40 |
| Employees | 2 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Alifarm Plus Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 6.563 | 9.713 | 3.065 | 662 | 6.637 | 400 | 305 | 171 | 373 | 320 |
| Inventories | 5.093 | 8.503 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 896 | 887 | 872 | 379 | 6.613 | 110 | 123 | 123 | 123 | 130 |
| Cash | 573 | 322 | 2.166 | 283 | 25 | 290 | 183 | 48 | 250 | 191 |
| Shareholders Funds | -13.400 | -16.055 | -17.136 | -15.563 | -14.096 | -14.002 | -13.818 | -13.901 | -13.900 | -13.862 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 19.963 | 25.768 | 20.201 | 16.224 | 20.734 | 14.402 | 14.123 | 14.073 | 14.273 | 14.183 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Alifarm Plus Srl